ALSO NOTED: Lilly wins patent fight; Canada OKs Tarceva; Vioxx trial begins; and much more...

> A US appeals court has upheld Eli Lilly's patent on Sarafem for premenstrual stress. Teva had challenged the patent saying it is an exact copy of Prozac, which is no longer under patent protection. Report

> Cryocor has priced its IPO at $11 per share. Report

> Canadian regulators have approved OSI's Tarceva for lung cancer. Report

> The first trial of Vioxx is set to begin after a jury was selected in the small Texas town of Angleton. Story

> Merck has acquired most of the global rights for the cancer treatment UFT for the treatment of colorectal cancer from Taiho Pharmaceutical. Release

> Acambis has launched a Phase II trial of a weakened smallpox vaccine for patients unable to take a full dose. Report

> The FDA has approved Ranbaxy's anti-retroviral drug Zidovudine for use outside the US. Story

And Finally... Scientists report that they have discovered a simple therapy to reduce the high risk of death from SARS. Article

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.